Cardiovascular Diseases Clinical Trial
— PLANTASTICOfficial title:
Plant Stanol Esters in the Prevention of Clinical Symptoms Related to Asthma: The PLANTASTIC Trial
Plant stanols are known to lower low-density lipoprotein cholesterol. However, studies have suggested that these compounds also influence the immune system. Asthmatic responses are predominantly T helper (Th)2 cell dependent, while plant stanols were previously found to activate Th1 cells and shift the immune response away from the Th2 cell dominant asthmatic response. The question now is whether this also translates into a reduction of clinical symptoms in asthma patients.The primary objective of this study is to demonstrate clinical benefits of prolonged consumption of plant stanols (delivered via plant stanol esters) in asthma patients. The secondary objectives are to evaluate the mechanisms via which plant stanols modulate the immune system and to evaluate the effects of plant stanol ester consumption on cardiovascular (CVD) risk parameters.
Status | Recruiting |
Enrollment | 160 |
Est. completion date | September 2024 |
Est. primary completion date | September 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - Diagnosed with allergic asthma (GINA step 1-4) which is in a stable phase at the moment of inclusion (defined as no changes in asthma control and lung function in (at least) the past three months) - Have been treated with prescribed asthma medication for at least one year - Aged 18-70 years old - BMI between 20 and 35 kg/m2 - Willing to abstain from products containing plant sterols or stanols one month prior to the study (products with a cholesterol lowering claim of Becel ProActiv, Benecol, Danacol, store brands) - Willing to abstain from products containing plant sterols or stanols during the study (products with a cholesterol lowering claim of Becel ProActiv, Benecol, Danacol, store brands) - Willing to keep the intake of fish oil supplements constant Exclusion Criteria: - Currently smoking or quitted smoking in the past year, with a maximum of 10 packyears as smoking history (packyears = packs per day * years of smoking) - Allergy to an ingredient of the soft chews - Suffering from inflammatory diseases (for CVD, illness must be minimally 3 years ago and currently under control in order to participate in the study) - Fasting plasma glucose > 7.0 mmol/L - Fasting serum TC > 8.0 mmol/L - Having donated blood within one month prior to the start of the study, or planning to donate blood during the study - Pregnant women - Breastfeeding women |
Country | Name | City | State |
---|---|---|---|
Netherlands | Maastricht University Medical Center | Maastricht | Limburg |
Lead Sponsor | Collaborator |
---|---|
Maastricht University Medical Center | Raisio Group, TKI Life Sciences and Health (LSH) |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Mechanistic outcomes for measuring the immune response | Vaccination response to vaccines against tetanus, pneumococcal bacteria and rabies | Weekly from T=12 months to T=13 months | |
Primary | Asthma control questionnaire score | The ACQ consists of seven questions: five questions are on asthma related symptoms, one on medication use and one on the FEV1. Participants are asked to score their symptoms and medication use of the past week on a scale from zero to six. The score of the ACQ is the average score on the seven questions. A score of zero means that asthma is fully controlled; a score of six means that asthma is severely uncontrolled. The minimal clinically important difference is 0.5. The ACQ has been validated and is widely use in research and clinical settings. | Change between T=0 months and T=12 months | |
Secondary | Asthma control questionnaire score | The ACQ consists of seven questions: five questions are on asthma related symptoms, one on medication use and one on the FEV1. Participants are asked to score their symptoms and medication use of the past week on a scale from zero to six. The score of the ACQ is the average score on the seven questions. A score of zero means that asthma is fully controlled; a score of six means that asthma is severely uncontrolled. The minimal clinically important difference is 0.5. The ACQ has been validated and is widely use in research and clinical settings. | T=0 months, T=3 months, T=6 months, T=9 months, T=12 months | |
Secondary | Forced expiratory volume in 1 second | Amount of air that can be exhaled forcefully in one second in Liters or % | T=0 months, T=3 months, T=6 months, T=9 months, T=12 months | |
Secondary | Forced vital capacity | Amount of air that can be exhaled forcefully in total in Liters or % | T=0 months, T=3 months, T=6 months, T=9 months, T=12 months | |
Secondary | Asthma related medication use | Self-reported medication use | Throughout 1 year | |
Secondary | Number of visits to the general practitioner or hospital | Self-reported amount of visits to the general practitioner or hospital | Throughout 1 year | |
Secondary | Incidence counts of exacerbations and other asthma related complaints | Self-reported amount of exacerbations and other asthma related complaints | Throughout 1 year | |
Secondary | Duration of exacerbations | Self-reported duration of exacerbations | Throughout 1 year | |
Secondary | Severity of exacerbations | Self-reported severity of exacerbations | Throughout 1 year | |
Secondary | Calculated disease load | Number x duration of exacerbations | Throughout 1 year | |
Secondary | Number of infections that occur throughout the study | Self-reported amount of infections | Throughout 1 year | |
Secondary | Leukocyte count | Number of leukocytes measured in EDTA plasma | T=0 months, T=3 months, T=6 months, T=9 months, T=12 months | |
Secondary | Leukocyte differential count | Number of subgroups of leukocytes measured in EDTA plasma | T=0 months, T=3 months, T=6 months, T=9 months, T=12 months | |
Secondary | Red blood cell count | Number of red blood cells measured in EDTA plasma | T=0 months, T=3 months, T=6 months, T=9 months, T=12 months | |
Secondary | Platelet count | Number of platelets measured in EDTA plasma | T=0 months, T=3 months, T=6 months, T=9 months, T=12 months | |
Secondary | Hematocrit | Hematocrit measured in EDTA plasma | T=0 months, T=3 months, T=6 months, T=9 months, T=12 months | |
Secondary | Hemoglobin | Hemoglobin measured in EDTA plasma | T=0 months, T=3 months, T=6 months, T=9 months, T=12 months | |
Secondary | Immune parameters (1) | Cytokine production by PBMCs after stimulation with antiCD3-antiCD28 antiCD28 antibodies using the TruCulture system | T=0 months, T=6 months, T=12 months | |
Secondary | Immune parameters (2) | Total IgE | T=0 months, T=3 months, T=6 months, T=9 months, T=12 months | |
Secondary | Immune parameters (3) | Total IgM | T=0 months, T=3 months, T=6 months, T=9 months, T=12 months | |
Secondary | Immune parameters (4) | hsCRP | T=0 months, T=3 months, T=6 months, T=9 months, T=12 months | |
Secondary | Fasted metabolism (1) | Serum lipid and lipoprotein profile | T=0 months, T=3 months, T=6 months, T=9 months, T=12 months | |
Secondary | Fasted metabolism (2) | Serum non-cholesterol sterols and stanols | T=0 months, T=3 months, T=6 months, T=9 months, T=12 months | |
Secondary | Fasted metabolism (3) | Plasma glucose metabolism | T=0 months, T=3 months, T=6 months, T=9 months, T=12 months | |
Secondary | Vascular function markers (1) | Carotid-femoral pulse wave velocity (PWV) | T=0 months and T=12 months | |
Secondary | Vascular function markers (2) | Pulse wave analysis (PWA) | T=0 months and T=12 months | |
Secondary | Vascular function markers (3) | Retinal microvascular caliber | T=0 months and T=12 months | |
Secondary | Cardiometabolic risk marker | Office blood pressure | T=0 months and T=12 months | |
Secondary | Cognitive function | CANTAB tests | T=0 months and T=12 months | |
Secondary | Anthropometry (1) | Body weight | T=0 months, T=3 months, T=6 months, T=9 months, T=12 months | |
Secondary | Anthropometry (2) | Height | T=0 months, T=3 months, T=6 months, T=9 months, T=12 months | |
Secondary | Anthropometry (3) | Body mass index | T=0 months, T=3 months, T=6 months, T=9 months, T=12 months | |
Secondary | Anthropometry (4) | Waist circumference | T=0 months, T=3 months, T=6 months, T=9 months, T=12 months | |
Secondary | Anthropometry (5) | Hip circumference | T=0 months, T=3 months, T=6 months, T=9 months, T=12 months | |
Secondary | Anthropometry (6) | Waist-to-hip ratio | T=0 months, T=3 months, T=6 months, T=9 months, T=12 months | |
Secondary | Quality of life score | 32-item questionnaire (including social, spiritual, emotional, cognitive, physical, activities of daily living, and integrated Quality of Life) | T=0 months, T=3 months, T=6 months, T=9 months, T=12 months | |
Secondary | Fatigue | Fatigue severity score (FSS), a 9-item questionnaire is used to determine the severity of fatigue a subject experienced in the past week during daily activities | T=0 months, T=3 months, T=6 months, T=9 months, T=12 months | |
Secondary | Physical activity | Baecke's questionnaire | T=0 months, T=3 months, T=6 months, T=9 months, T=12 months | |
Secondary | Mood | Affect grid | T=0 months, T=3 months, T=6 months, T=9 months, T=12 months | |
Secondary | Diet | Food frequency questionnaire is used to determine if the participants maintain their habitual diet and to determine if the participants do not consume plant stanols and/or sterols outside the intervention | T=0 months, T=6 months, T=12 months | |
Secondary | Immune cell characterisation | Fluorescence-activated cell sorting (FACS) | T=0 months, T=6 months, T=12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|